KyungdongPharm
KOSDAQ
₩5,080.00
-0.97%
Delayed · cached 15 min
Fair value analysis
011040
KyungdongPharm
₩5,080.00
Close used for this calculation
₩5,126.60Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
46/100
Quality radar
Consensus fair value
₩5,126.60
Near FV▲ +0.9% against the close used
Model range ₩815.03 – ₩7,454.35
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear₩815.03Fair value₩5,126.60Bull₩7,454.35
FairClose
52-week traded range
52W low ₩4,750.0052W high ₩5,180.00
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading close to the consensus fair value
KyungdongPharm closed at ₩5,080.00, 0.9% below the consensus fair value of ₩5,126.60 drawn from 10 valuation models.
Financial DNA score 46/100 — Average. P/E of 16.1x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
₩5,922.64
+16.6%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
Graham Number
₩7,454.35
+46.7%
√(22.5 × EPS × BVPS)
EPS=316, BVPS=7815.38
Graham Formula
₩3,581.33
-29.5%
EPS × (8.5 + 2g) × 4.4 ÷ FD_Rate
g=0%, FD=3.3%
P/E Fair Value
₩6,320.00
+24.4%
EPS × 20x (sector P/E)
EPS=316, Sector P/E=20x
Peter Lynch (PEG)
₩4,825.32
-5.0%
EPS × Growth% (PEG = 1 is fair)
EPS=316, g=15.3%
EV/EBITDA
₩2,955.09
-41.8%
(EBITDA × 10x − Net Debt) ÷ Shares
EBITDA=10.9B
Dividend Discount (DDM)
₩3,173.73
-37.5%
D1 ÷ (r − g) where D1 = D0×(1+g)
D0=248.92, r=10%, g=2%
Book Value (P/B)
₩815.03
-84.0%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=7815.38, ROE=3.7%, g=3%, r=10%
Reverse DCF
₩5,080.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 4.2% | Historical: -15.3%
Margin of Safety
₩4,364.68
-14.1%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=5819.58, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.